Novan's (NOVN) stock is trading at nearly double last month's $11 IPO price and with a pair of Phase III trials coming up for its dermatological drug, CEO Nate Stasko says the company is merely piercing the skin of its long-term potential. Stasko estimated between 40 and 50 million Americans suffer from acne vulgaris and can be helped by his nitric oxide-based treatment. Nitric oxide is made in the skin by almost every cell type. It has a natural role in barrier repair, wound healing, host defense against invading microbes, and as a modulator of inflammatory processes. But in many chronic inflammatory skin diseases and in skin infections, the body's systems fail and require a boost of nitric oxide to 'reprogram' the system or kill bacteria, viruses, or fungi. Novan's two, identically designed Phase 3 pivotal clinical trials will evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 Gel in the treatment of acne vulgaris. These two trials aim to demonstrate the safety and efficacy of SB204 in over 2600 patients with acne vulgaris.

More from Video

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Market Movers: September Grain Stocks Report

Market Movers: September Grain Stocks Report

We Asked Our Pros About the Longevity of the Bull Market

We Asked Our Pros About the Longevity of the Bull Market

Legendary Technician Gives Her View of the Current Market

Legendary Technician Gives Her View of the Current Market

Cannabis: Why It May End Up in Your Portfolio

Cannabis: Why It May End Up in Your Portfolio